U.S. generics drugmaker Mylan said on Thursday that the United States Patent and Trademark Office had rejected Sanofi's infringement claims relating to insulin drug Lantus.

EU agency casts further doubt on Lantus cancer risk Drugs watchdog asks Sanofi for further research Sanofi says statement "reassuring" for Lantus patients Sanofi shares close up 1.2 percent ...